Patents by Inventor Kazuya Kano
Kazuya Kano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240093251Abstract: The present invention relates to a method for producing an amide compound from a nitrile compound in the presence of a biocatalyst having nitrile hydratase activity, wherein the amide compound is efficiently produced by suppressing a deactivation of the biocatalyst, and improving the rate of conversion reaction from the nitrile compound to the amide compound.Type: ApplicationFiled: August 10, 2023Publication date: March 21, 2024Applicant: Mitsubishi Chemical CorporationInventors: Takafumi Yamaguchi, Norifumi Hagiya, Makoto Kano, Kazuya Takanashi
-
Patent number: 11008320Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: GrantFiled: July 24, 2020Date of Patent: May 18, 2021Assignee: SHIONOGI & CO., LTD.Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Motohiro Fujiu, Hiroki Yamaguchi
-
Publication number: 20200354358Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: July 24, 2020Publication date: November 12, 2020Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Patent number: 10781210Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, —A— is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: GrantFiled: November 15, 2019Date of Patent: September 22, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Takatsugu Inoue, Motohiro Fujiu
-
Patent number: 10640495Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.Type: GrantFiled: July 6, 2016Date of Patent: May 5, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Kenichiroh Nakamura, Masanao Inagaki, Kazuya Kano, Motohiro Fujiu, Hiroki Yamaguchi, Kayoko Hata, Takatsugu Inoue
-
Publication number: 20200087302Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: November 15, 2019Publication date: March 19, 2020Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Patent number: 10532985Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: GrantFiled: October 31, 2018Date of Patent: January 14, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Tohru Horiguchi, Kazuya Kano
-
Patent number: 10533006Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: GrantFiled: February 3, 2017Date of Patent: January 14, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Kazuya Kano, Tohru Horiguchi, Kenichiroh Nakamura, Motohiro Fujiu, Hiroki Yamaguchi
-
Publication number: 20190062282Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: ApplicationFiled: October 31, 2018Publication date: February 28, 2019Applicant: Shionogi & Co., Ltd.Inventors: Akira YUKIMASA, Kenichiroh NAKAMURA, Tohru HORIGUCHI, Kazuya KANO, Takatsugu INOUE
-
Publication number: 20190047998Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: February 3, 2017Publication date: February 14, 2019Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Publication number: 20180201607Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.Type: ApplicationFiled: July 6, 2016Publication date: July 19, 2018Inventors: Akira YUKIMASA, Kenichiroh NAKAMURA, Masanao INAGAKI, Kazuya KANO, Motohiro FUJIU, Hiroki YAMAGUCHI, Kayoko HATA, Takatsugu INOUE
-
Publication number: 20170240512Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: ApplicationFiled: August 5, 2015Publication date: August 24, 2017Applicant: Shionogi & Co., Ltd.Inventors: Akira YUKIMASA, Iori KOZONO, Kenichiroh NAKAMURA, Tohru HORIGUCHI, Kazuya KANO, Takatsugu INOUE
-
Publication number: 20120238588Abstract: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.Type: ApplicationFiled: March 27, 2012Publication date: September 20, 2012Inventors: James S. Frazee, Marlys Hammond, Sharada Manns, Scott Kevin Thompson, David G. Washburn, Kazuya Kano, Hiroko Nakamura
-
Publication number: 20120135997Abstract: The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid ? proteins. The present invention provides a pharmaceutical composition for suppressing amyloid ? production comprising a compound of the formula: wherein A is a benzene ring, a pyridine ring or a pyrimidine ring, X is sultam, lactam, sulfonamide or the like, C is substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl or the like, R2, R3 and R4 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or the like, its pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: July 15, 2010Publication date: May 31, 2012Applicant: Shionogi & Co., Ltd.Inventors: Issei Kato, Kazuya Kano
-
Publication number: 20110105457Abstract: The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prevention/treatment of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. This was achieved by providing a substituted 2-amino-5,6-nitrogenated fused ring compound shown in the present specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 16, 2009Publication date: May 5, 2011Inventors: Daisuke Taniyama, Kazuya Kano, Kazuya Okamoto, Masahiko Fujioka, Yasunori Mitsuoka
-
Publication number: 20090270456Abstract: This invention relates to newly identified compounds for inhibiting hYAK3 and/or CK2 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 and/or CK2 proteins.Type: ApplicationFiled: January 6, 2005Publication date: October 29, 2009Inventors: Masaichi Hasegawa, Kazuya Kano, Masato Nakano, Mariko Yamabe
-
Publication number: 20090233955Abstract: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.Type: ApplicationFiled: December 8, 2005Publication date: September 17, 2009Inventors: James S. Frazee, Marlys Hammond, Sharada Manns, Scott Kevin Thompson, David G. Washburn, Kazuya Kano, Hiroko Nakamura
-
Publication number: 20070249600Abstract: Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: ApplicationFiled: June 15, 2007Publication date: October 25, 2007Inventors: Mui Cheung, Philip Harris, Masaichi Hasegawa, Satoru Ida, Kazuya Kano, Naohiko Nishigaki, Hideyuki Sato, James Veal, Yoshiaki Washio, Rob West
-
Patent number: 7238813Abstract: Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: GrantFiled: November 28, 2001Date of Patent: July 3, 2007Assignee: Smithkline Beecham CorporationInventors: Mui Cheung, Philip Anthony Harris, Masaichi Hasegawa, Satoru Ida, Kazuya Kano, Naohiko Nishigaki, Hideyuki Sato, James Marvin Veal, Yoshiaki Washio, Rob I. West
-
Publication number: 20060167020Abstract: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.Type: ApplicationFiled: July 21, 2003Publication date: July 27, 2006Inventors: Scott Dickerson, Dulce Garrido, Wendy Mills, Kazuya Kano, Andrew Peat, Stephen Thomson, Jayme Wilson, Hui-Quiang Zhou